patents.google.com

SG11201907804QA - Pharmaceutical composition comprising selexipag - Google Patents

  • ️Fri Sep 27 2019

SG11201907804QA - Pharmaceutical composition comprising selexipag - Google Patents

Pharmaceutical composition comprising selexipag

Info

Publication number
SG11201907804QA
SG11201907804QA SG11201907804QA SG11201907804QA SG11201907804QA SG 11201907804Q A SG11201907804Q A SG 11201907804QA SG 11201907804Q A SG11201907804Q A SG 11201907804QA SG 11201907804Q A SG11201907804Q A SG 11201907804QA SG 11201907804Q A SG11201907804Q A SG 11201907804QA Authority
SG
Singapore
Prior art keywords
international
pct
compositions
aqueous
gewerbestrasse
Prior art date
2017-03-08
Application number
SG11201907804QA
Inventor
Klaus Hellerbrand
Alexandra Schlicker-Spain
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
2017-03-08
Filing date
2018-03-07
Publication date
2019-09-27
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61655736&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201907804Q(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
2018-03-07 Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
2019-09-27 Publication of SG11201907804QA publication Critical patent/SG11201907804QA/en

Links

  • 239000008194 pharmaceutical composition Substances 0.000 title abstract 5
  • QXWZQTURMXZVHJ-UHFFFAOYSA-N selexipag Chemical compound C=1C=CC=CC=1C1=NC(N(CCCCOCC(=O)NS(C)(=O)=O)C(C)C)=CN=C1C1=CC=CC=C1 QXWZQTURMXZVHJ-UHFFFAOYSA-N 0.000 title abstract 2
  • 229960003841 selexipag Drugs 0.000 title abstract 2
  • 239000000203 mixture Substances 0.000 abstract 3
  • GJPICJJJRGTNOD-UHFFFAOYSA-N bosentan Chemical compound COC1=CC=CC=C1OC(C(=NC(=N1)C=2N=CC=CN=2)OCCO)=C1NS(=O)(=O)C1=CC=C(C(C)(C)C)C=C1 GJPICJJJRGTNOD-UHFFFAOYSA-N 0.000 abstract 2
  • 229960003065 bosentan Drugs 0.000 abstract 2
  • 239000003795 chemical substances by application Substances 0.000 abstract 2
  • 239000003814 drug Substances 0.000 abstract 2
  • 102220240796 rs553605556 Human genes 0.000 abstract 2
  • DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 1
  • 229920001213 Polysorbate 20 Polymers 0.000 abstract 1
  • 108091006335 Prostaglandin I receptors Proteins 0.000 abstract 1
  • 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 abstract 1
  • 150000001875 compounds Chemical class 0.000 abstract 1
  • 208000037765 diseases and disorders Diseases 0.000 abstract 1
  • 238000001990 intravenous administration Methods 0.000 abstract 1
  • 238000000034 method Methods 0.000 abstract 1
  • 230000008520 organization Effects 0.000 abstract 1
  • 239000008363 phosphate buffer Substances 0.000 abstract 1
  • 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 abstract 1
  • 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 abstract 1
  • 229940068977 polysorbate 20 Drugs 0.000 abstract 1

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 13 September 2018 (13.09.2018) WIP0 I PCT oimiolollm °noI0 OilIIIIIOHIIIII010m Oila° oimIE (10) International Publication Number WO 2018/162527 Al (51) International Patent Classification: A61K 47/10 (2017.01) A61P 17/02 (2006.01) A61K 9/19 (2006.01) A61P 9/12 (2006.01) A61K 31/4965 (2006.01) (21) International Application Number: PCT/EP2018/055551 (22) International Filing Date: 07 March 2018 (07.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: PCT/EP2017/055406 08 March 2017 (08.03.2017) EP (71) Applicant: ACTELION PHARMACEUTICALS LTD [CH/CH]; Gewerbestrasse 16, 4123 Allschwil (CH). (72) Inventors: HELLERBRAND, Klaus; c/o ProJect Phar- maceutics GmbH, Fraunhoferstrasse 22, 82152 Martinsried (DE). SCHLICKER-SPAIN, Alexandra; c/o Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, 4123 Allschwil (CH). (74) Agent: SCHAGER, Frank; Gewerbestrasse 16, 4123 Allschwil (CH). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.1700) Published: with international search report (Art. 21(3)) 11 N N (54) Title: PHARMACEUTICAL COMPOSITION COMPRISING SELEXIPAG 1 1 ei (57) : The invention relates to aqueous pharmaceutical compositions comprising the compound 2-{44N-(5,6- diphenylpyrazin-2-y1)-N-isopropylamino]butyloxy} -N-(methylsulfonyl) acetamide; glycine; polysorbate 20; and an aqueous phosphate buffer, wherein the relative amounts are as described in the description, wherein the pH of said pharmaceutical composition is between wc ' s about 7 and 8; to lyophilized pharmaceutical compositions prepared from said aqueous compositions, and to reconstituted aqueous © compositions thereof which are suitable for i.v. administration. The invention further relates to processes for the preparation of said f'1 compositions, and to their use for the treatment of diseases and disorders which are related to IP receptor.

SG11201907804QA 2017-03-08 2018-03-07 Pharmaceutical composition comprising selexipag SG11201907804QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2017055406 2017-03-08
PCT/EP2018/055551 WO2018162527A1 (en) 2017-03-08 2018-03-07 Pharmaceutical composition comprising selexipag

Publications (1)

Publication Number Publication Date
SG11201907804QA true SG11201907804QA (en) 2019-09-27

Family

ID=61655736

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201907804QA SG11201907804QA (en) 2017-03-08 2018-03-07 Pharmaceutical composition comprising selexipag

Country Status (27)

Country Link
US (1) US12121516B2 (en)
EP (1) EP3592391B1 (en)
JP (1) JP6964679B2 (en)
KR (1) KR102593075B1 (en)
CN (1) CN110430900B (en)
AR (1) AR111570A1 (en)
AU (1) AU2018229750B2 (en)
BR (1) BR112019018420A2 (en)
CA (1) CA3055010A1 (en)
CL (1) CL2019002511A1 (en)
CO (1) CO2019009221A2 (en)
CR (1) CR20190455A (en)
DO (1) DOP2019000250A (en)
EA (1) EA201992074A1 (en)
EC (1) ECSP19072294A (en)
ES (1) ES2880009T3 (en)
IL (1) IL269061A (en)
JO (1) JOP20190204A1 (en)
MA (1) MA47816A (en)
MX (1) MX391339B (en)
NI (1) NI201900090A (en)
PE (1) PE20191492A1 (en)
PH (1) PH12019502033A1 (en)
PL (1) PL3592391T3 (en)
SG (1) SG11201907804QA (en)
TW (1) TWI764996B (en)
WO (1) WO2018162527A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022532076A (en) * 2019-05-06 2022-07-13 アクテリオン ファーマシューティカルズ リミテッド Treatment of sarcoidosis-related pulmonary hypertension
EP3982967A1 (en) * 2019-06-11 2022-04-20 Actelion Pharmaceuticals Ltd. Methods for treating pulmonary arterial hypertension
IL292354A (en) 2019-10-23 2022-06-01 Actelion Pharmaceuticals Ltd A pharmaceutical preparation containing Selexifag
US20230113077A1 (en) 2020-01-31 2023-04-13 Actelion Pharmaceuticals Ltd Controlled release selexipag composition
TW202239408A (en) 2021-01-29 2022-10-16 瑞士商艾克泰聯製藥有限公司 Pharmaceutical composition comprising a diphenylpyrazine derivative
WO2022215045A1 (en) * 2021-04-08 2022-10-13 Glenmark Pharmaceutical Limited Lyophilized composition comprising selexipag
WO2023131608A1 (en) 2022-01-04 2023-07-13 Actelion Pharmaceuticals Ltd Controlled release compositions
WO2023209731A1 (en) * 2022-04-25 2023-11-02 Msn Laboratories Private Limited, R&D Center Injectable liquid or lyophilized powder dosage forms of selexipag and their method of preparation
WO2023214059A1 (en) 2022-05-06 2023-11-09 Actelion Pharmaceuticals Ltd Diphenylpyrazine compounds as prodrugs
WO2023238952A1 (en) * 2022-06-10 2023-12-14 日本新薬株式会社 Pharmaceutical composition
WO2024017964A1 (en) 2022-07-20 2024-01-25 Actelion Pharmaceuticals Ltd Injectable pharmaceutical composition comprising a diphenylpyrazine derivative
WO2024133620A1 (en) 2022-12-22 2024-06-27 Actelion Pharmaceuticals Ltd In vitro dissolution test
TW202444370A (en) 2023-03-23 2024-11-16 瑞士商艾克泰聯製藥有限公司 Pharmaceutical composition comprising a diphenylpyrazine derivative
KR20250008015A (en) * 2023-07-06 2025-01-14 재단법인대구경북과학기술원 Pharmaceutical composition for prevention or treatment of neurodegenerative diseases comprising selexipag

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI316055B (en) 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
SI1478339T1 (en) * 2002-02-22 2008-10-31 Schering Corp Pharmaceutical formulations of antineoplastic agents, in particular temozolomide, processes of making and using the same
AU2009218115B2 (en) 2008-02-28 2013-05-30 Nippon Shinyaku Co., Ltd. Fibrosis inhibitor
WO2009154246A1 (en) 2008-06-19 2009-12-23 日本新薬株式会社 Therapeutic agent for erectile dysfunction
ES2611483T3 (en) 2008-06-23 2017-05-09 Nippon Shinyaku Co., Ltd. Therapeutic agent for inflammatory bowel disease
WO2009157397A1 (en) 2008-06-23 2009-12-30 日本新薬株式会社 Therapeutic agent for intestinal tract injury accompanying administration of a non-steroid anti-inflammatory agent
EP2292231B1 (en) 2008-06-23 2015-10-21 Nippon Shinyaku Co., Ltd. Therapeutic agent for spinal canal stenosis
HUE048467T2 (en) * 2009-06-26 2020-07-28 Nippon Shinyaku Co Ltd Crystals
WO2011024874A1 (en) 2009-08-26 2011-03-03 日本新薬株式会社 Base addition salts
KR20140053881A (en) * 2011-04-19 2014-05-08 릭스하스피탈렛 Prostacyclin and analogs thereof administered during surgery for prevention and treatment of capillary leakage
AU2012296953B2 (en) 2011-08-12 2016-10-20 Ascendis Pharma A/S Sustained release composition of prostacyclin
JP6400479B2 (en) 2012-10-29 2018-10-03 株式会社カルディオ Lung disease specific therapeutic agent
IL312865B1 (en) * 2013-09-11 2025-02-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
GB201400412D0 (en) * 2014-01-10 2014-02-26 Heart Biotech Ltd Pharmaceutical formulations for the treatment of pulmonary arterial hypertension
WO2017029594A1 (en) 2015-08-17 2017-02-23 Dr. Reddy's Laboratories Limited Processes for preparation of selexipag and its amorphous form
EP3344607B1 (en) * 2015-09-03 2019-11-06 Teva Pharmaceuticals International GmbH Solid state forms of selexipag
AU2016366073B2 (en) 2015-12-02 2021-08-26 Nippon Shinyaku Co., Ltd. Pharmaceutical composition containing 2-{4-[N-(5,6- diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N- (methylsulfonyl)acetamide
EP3192502A1 (en) * 2016-01-15 2017-07-19 Sandoz Ag Pharmaceutical composition of selexipag

Also Published As

Publication number Publication date
KR20190122803A (en) 2019-10-30
CN110430900B (en) 2023-09-19
PH12019502033A1 (en) 2020-06-15
PE20191492A1 (en) 2019-10-21
JP2020509070A (en) 2020-03-26
WO2018162527A1 (en) 2018-09-13
IL269061A (en) 2019-11-28
US12121516B2 (en) 2024-10-22
ES2880009T3 (en) 2021-11-23
MX391339B (en) 2025-03-21
CA3055010A1 (en) 2018-09-13
MX2019010598A (en) 2019-10-15
MA47816A (en) 2020-01-15
CL2019002511A1 (en) 2020-01-17
TW201842910A (en) 2018-12-16
KR102593075B1 (en) 2023-10-23
JP6964679B2 (en) 2021-11-10
AR111570A1 (en) 2019-07-31
EA201992074A1 (en) 2020-02-27
US20200129506A1 (en) 2020-04-30
PL3592391T3 (en) 2021-11-02
CN110430900A (en) 2019-11-08
ECSP19072294A (en) 2019-11-30
BR112019018420A2 (en) 2020-04-14
AU2018229750A1 (en) 2019-09-12
TWI764996B (en) 2022-05-21
JOP20190204A1 (en) 2019-09-05
NI201900090A (en) 2020-03-11
AU2018229750B2 (en) 2023-11-23
EP3592391B1 (en) 2021-04-21
CR20190455A (en) 2019-11-12
CO2019009221A2 (en) 2019-08-30
EP3592391A1 (en) 2020-01-15
DOP2019000250A (en) 2020-09-15

Similar Documents

Publication Publication Date Title
SG11201907804QA (en) 2019-09-27 Pharmaceutical composition comprising selexipag
SG11201907604UA (en) 2019-09-27 Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan
SG11201810628XA (en) 2018-12-28 Nasal pharmaceutical compositions with a porous excipient
SG11201807913XA (en) 2018-10-30 Stabilized soluble pre-fusion rsv f proteins
SG11201807912SA (en) 2018-10-30 Vaccine against rsv
SG11201808566WA (en) 2018-11-29 Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide
SG11201809908TA (en) 2018-12-28 Stabilized glycopeptide antibiotic formulations
SG11201408095XA (en) 2015-01-29 Fibroblast growth factor 21 proteins
SG11201900633XA (en) 2019-02-27 Piperidine cxcr7 receptor modulators
SG11201407580YA (en) 2014-12-30 Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201809751XA (en) 2018-12-28 Egfr inhibitor compounds
SG11201900443VA (en) 2019-02-27 Spiro-lactam nmda receptor modulators and uses thereof
SG11201810280YA (en) 2018-12-28 Spiro-lactam nmda receptor modulators and uses thereof
SG11201901986SA (en) 2019-04-29 Process for the manufacture of a solid pharmaceutical adminstration form
SG11201900558RA (en) 2019-02-27 Spiro-lactam nmda receptor modulators and uses thereof
SG11201901534VA (en) 2019-03-28 Combination therapy with controlled-release cnp agonists
SG11201906436VA (en) 2019-08-27 Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201900551WA (en) 2019-02-27 Spiro-lactam nmda receptor modulators and uses thereof
SG11201900546UA (en) 2019-02-27 Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201810429UA (en) 2018-12-28 Anti-cd19 antibody formulations
SG11201810078PA (en) 2018-12-28 Stabilized pre-fusion rsv f proteins
SG11201908660RA (en) 2019-10-30 N-substituted indole derivatives
SG11201809172WA (en) 2018-11-29 Crystalline forms of n-[2-(3-hydroxy-3-methylbutyl)-6-(2-hydroxypropan-2-yl)-2h-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide
SG11201810801QA (en) 2019-01-30 Brain delivery protein
SG11201809882XA (en) 2018-12-28 Pharmaceutical combinations for treating cancer